We have located links that may give you full text access.
Clinical Trial
Journal Article
Randomized Controlled Trial
The impact of sertraline on psychomotor performance.
Aviation, Space, and Environmental Medicine 2002 October
INTRODUCTION: Aircrew receiving treatment for depression are grounded during treatment and follow-up observation, generally amounting to at least 1 yr. Selective serotonin re-uptake inhibitors (SSRls) offer new treatment options for depression, of which sertraline (Zoloft) has the least imposing side-effect profile. There has been considerable interest in the possibility of returning aircrew to restricted flying duties once stablized on an SSRI with resolution of depression. This study was undertaken to determine whether or not sertraline effects psychomotor performance.
METHOD: There were 19 volunteer non-depressed subjects (12 men and 7 women) who were assessed for psychomotor performance during placebo and sertraline treatment, in a double-blind cross-over protocol in counter-balanced order. Each treatment arm lasted 5 wk and involved ingesting one capsule each morning. The daily sertraline dose was 50 mg during week 1, 100 mg during week 2, and 150 mg during weeks 3, 4, and 5. Subjects completed a drug side-effect questionnaire and were tested on two psychomotor test batteries once per week, on the same weekday, at the same time of day throughout each 5-wk treatment period.
RESULTS: There was no significant effect of sertraline on serial reaction time, logical reasoning, serial subtraction, or multitask performance. With respect to drug side effects, there was a main effect of drugs on "getting to sleep" (p < 0.002), "awakenings" (p < 0.007), "returning to sleep" (p < 0.001), "dry mouth" (p < 0.016), "nausea" (p < 0.001), "diarrhea" (p < 0.026), "tremors" (p < 0.005), and "sweating" (p < 0.016), as well as a drug x trials interaction for "drowsiness" (p < 0.012), "libido" (p < 0.039), and "difficulty with ejaculation" (p < 0.001). There was no effect of sertraline on dizziness.
CONCLUSIONS: While we found some of the expected side effects due to sertraline, there was no effect on psychomotor performance. These findings support the possibility of selected use in aircrew and should be helpful in the ongoing aeromedical discussion about this evolving issue.
METHOD: There were 19 volunteer non-depressed subjects (12 men and 7 women) who were assessed for psychomotor performance during placebo and sertraline treatment, in a double-blind cross-over protocol in counter-balanced order. Each treatment arm lasted 5 wk and involved ingesting one capsule each morning. The daily sertraline dose was 50 mg during week 1, 100 mg during week 2, and 150 mg during weeks 3, 4, and 5. Subjects completed a drug side-effect questionnaire and were tested on two psychomotor test batteries once per week, on the same weekday, at the same time of day throughout each 5-wk treatment period.
RESULTS: There was no significant effect of sertraline on serial reaction time, logical reasoning, serial subtraction, or multitask performance. With respect to drug side effects, there was a main effect of drugs on "getting to sleep" (p < 0.002), "awakenings" (p < 0.007), "returning to sleep" (p < 0.001), "dry mouth" (p < 0.016), "nausea" (p < 0.001), "diarrhea" (p < 0.026), "tremors" (p < 0.005), and "sweating" (p < 0.016), as well as a drug x trials interaction for "drowsiness" (p < 0.012), "libido" (p < 0.039), and "difficulty with ejaculation" (p < 0.001). There was no effect of sertraline on dizziness.
CONCLUSIONS: While we found some of the expected side effects due to sertraline, there was no effect on psychomotor performance. These findings support the possibility of selected use in aircrew and should be helpful in the ongoing aeromedical discussion about this evolving issue.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app